Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency
The DOI matches its Crossref record.
Abstract
Alipogene tiparvovec is the first adeno-associated virus (AAV)-mediated gene therapy to be approved for the treatment of a metabolic disorder. Lipoprotein lipase (LPL) deficiency (LPLD) is a rare autosomal-recessive disorder in which gene mutations cause the production of a catalytically inactive enzyme required for plasma triglyceride hydrolysis. The resultant hypertriglyceridemia causes frequent abdominal pain, fatty deposits in the skin and retina, and can lead to potentially fatal pancreatitis. In addition, patients with LPLD can develop diabetes and cardiovascular disease. Past therapies to lower plasma triglycerides in these patients have been ineffective. Intramuscular injection of alipogene tiparvovec delivers a natural gain-of-function LPL gene variant, LPLS447X, to muscle tissue and has demonstrated efficacy in animal models of LPLD. In phase I/II and phase II/III clinical evaluations, alipogene tiparvovec significantly lowered plasma triglycerides and increased LPL activity, resulting in a reduction in plasma chylomicron and a decrease in the frequency of pancreatitis episodes. The therapy is well tolerated in animals and humans and produces no serious treatment-related adverse effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Thirty years of baculovirus–insect cell protein expression: from dark horse to mainstream technology
van Oers, M. M., Pijlman, G. P., & Vlak, J. M. (2015) · Journal of General Virology · doi:10.1099/vir.0.067108-0 · Cited by 348
Postprandial hypertriglyceridemia as a coronary risk factor
Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182
György, B., Fitzpatrick, Z., Crommentuijn, M. H. W., Mu, D., & Maguire, C. A. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.032 · Cited by 153
Gene Transfer Properties and Structural Modeling of Human Stem Cell-derived AAV
Smith, L. J., Ul-Hasan, T., Carvaines, S. K., Van Vliet, K., Yang, E., Wong, K. K., Agbandje-McKenna, M., & Chatterjee, S. (2014) · Molecular Therapy · doi:10.1038/mt.2014.107 · Cited by 51
Butterfield, J. S. S., Biswas, M., Shirley, J. L., Kumar, S. R. P., Sherman, A., Terhorst, C., Ling, C., & Herzog, R. W. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.013 · Cited by 35
“The first gene therapy drug approved in the Western world also utilized AAV gene transfer to muscle.(4) Besides for correction of muscle disorders, muscle-directed gene therapy has strong potential for delivery of therapeutic proteins into systemic circulation, including coagulation factors, a1-antitrypsin, lipoprotei…”
Background
Metadata
- Authors
- Haddley, K.
- Venue
- Drugs of Today
- Publisher
- Portico
- Published
- 2013
- Volume
- 49
- Issue
- 3
- Pages
- 161
- ISSN
- 0025-7656 (ISSN-L)
- 1699-4019
- OpenAlex
- W135142038
- Cited by
- 22
- References
- 0
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. https://app.cochat.ai/papers/10.1358/dot.2013.49.3.1937398
- The paper
- Haddley, K. (2013). Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs of Today. https://doi.org/10.1358/dot.2013.49.3.1937398
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.